Cargando…
Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
We have conducted a Phase I trial to determine the maximum tolerated dose of CPT-11 together with a fixed dose of cisplatin in patients with advanced lung cancer, and the dose-limiting toxicities of this combination. Fourteen previously untreated patients with stage IIIB or IV disease were treated w...
Autores principales: | Masuda, N., Fukuoka, M., Kudoh, S., Kusunoki, Y., Matsui, K., Takifuji, N., Nakagawa, K., Tamanoi, M., Nitta, T., Hirashima, T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968602/ https://www.ncbi.nlm.nih.gov/pubmed/8398707 |
Ejemplares similares
-
Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin
por: Kudoh, Shinzoh, et al.
Publicado: (1995) -
Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
por: Negoro, S, et al.
Publicado: (2003) -
Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts
por: Kudoh, Shinzoh, et al.
Publicado: (1993) -
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
por: Takeda, K, et al.
Publicado: (1999) -
Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
por: Yamamoto, N, et al.
Publicado: (2004)